Integrum appoints Director of Quality Assurance and Regulatory Affairs

Mölndal, Sweden, January 20, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has appointed Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, QARA. Annika Fahlén will join the company on 1 April 2023 and will be part of the management team.

Annika Fahlén has vast experience in the field of Quality Assurance and Regulatory Affairs working at Mölnlycke, Getinge, Qing and Abigo. She will join Integrum from a position as Regulatory Affairs Quality Assurance Director at Essity.

“We are happy to welcome Annika Fahlén to Integrum. She is acknowledged for her business focus and ability to implement efficiency and improvements in an organization. Her knowledge and experience will be a great contribution to our management team as quality assurance and regulatory affairs are crucial in our ongoing international expansion,” says Rickard Brånemark, CEO of Integrum.

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.